Log in

NYSE:TXG10x Genomics Stock Price, Forecast & News

-0.79 (-0.79 %)
(As of 08/6/2020 04:00 PM ET)
Today's Range
Now: $99.21
50-Day Range
MA: $91.71
52-Week Range
Now: $99.21
Volume206,391 shs
Average Volume643,673 shs
Market Capitalization$9.76 billion
P/E RatioN/A
Dividend YieldN/A
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems. The company serves researchers in approximately 40 countries. Its customers include a range of academic, government, biopharmaceutical, biotechnology, and other institutions worldwide. 10X Genomics, Inc. was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. The company was incorporated in 2012 and is based in Pleasanton, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars

Industry, Sector and Symbol

Industry Health Information Services



Sales & Book Value

Annual SalesN/A



Market Cap$9.76 billion
Next Earnings Date8/11/2020 (Confirmed)
OptionableNot Optionable
-0.79 (-0.79 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TXG News and Ratings via Email

Sign-up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

10x Genomics (NYSE:TXG) Frequently Asked Questions

How has 10x Genomics' stock been impacted by COVID-19 (Coronavirus)?

10x Genomics' stock was trading at $60.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TXG stock has increased by 63.3% and is now trading at $99.21.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of 10x Genomics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for 10x Genomics

When is 10x Genomics' next earnings date?

10x Genomics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for 10x Genomics

How can I listen to 10x Genomics' earnings call?

10x Genomics will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were 10x Genomics' earnings last quarter?

10x Genomics (NYSE:TXG) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.09. The company had revenue of $71.91 million for the quarter, compared to the consensus estimate of $71.67 million. The firm's revenue was up 34.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.25) EPS.
View 10x Genomics' earnings history

What price target have analysts set for TXG?

7 analysts have issued 1 year price targets for 10x Genomics' shares. Their forecasts range from $62.00 to $105.00. On average, they expect 10x Genomics' share price to reach $92.57 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for 10x Genomics

Has 10x Genomics been receiving favorable news coverage?

News headlines about TXG stock have trended positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. 10x Genomics earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about 10x Genomics

Who are some of 10x Genomics' key competitors?

What other stocks do shareholders of 10x Genomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 10x Genomics investors own include Alibaba Group (BABA), Verizon Communications (VZ), NVIDIA (NVDA), salesforce.com (CRM), Cisco Systems (CSCO), QUALCOMM (QCOM), Walt Disney (DIS), Intel (INTC), Johnson & Johnson (JNJ) and ServiceNow (NOW).

Who are 10x Genomics' key executives?

10x Genomics' management team includes the following people:
  • Dr. Serge Saxonov, Co-Founder, CEO & Director (Age 42)
  • Dr. Benjamin J. Hindson Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 44)
  • Mr. Justin J. McAnear, Chief Financial Officer (Age 44)
  • Mr. Paul W. Wyatt, VP of Operations
  • Mr. Eric S. Whitaker, Gen. Counsel (Age 52)

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the New York Stock Exchange (NYSE) under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (0.33%), Sumitomo Mitsui Trust Holdings Inc. (0.21%), Financial Consulate Inc. (0.20%), Asymmetry Capital Management L.P. (0.05%), Hussman Strategic Advisors Inc. (0.02%) and Emerald Advisers LLC (0.02%). Company insiders that own 10x Genomics stock include Associates Vi LP Venrock, Benjamin J Hindson, Bryan E Roberts, Foresite Capital Fund I, LP, Foresite Capital Management I,, John R Stuelpnagel and Serge Saxonov.
View institutional ownership trends for 10x Genomics

Which institutional investors are selling 10x Genomics stock?

TXG stock was sold by a variety of institutional investors in the last quarter, including Financial Consulate Inc., Hussman Strategic Advisors Inc., and Emerald Advisers LLC. Company insiders that have sold 10x Genomics company stock in the last year include Associates Vi LP Venrock, Benjamin J Hindson, Bryan E Roberts, Foresite Capital Management I,, John R Stuelpnagel, and Serge Saxonov.
View insider buying and selling activity for 10x Genomics

Which institutional investors are buying 10x Genomics stock?

TXG stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Sumitomo Mitsui Trust Holdings Inc., Asymmetry Capital Management L.P., Steward Partners Investment Advisory LLC, Principal Financial Group Inc., K.J. Harrison & Partners Inc, Paragon Advisors LLC, and Hamilton Lane Advisors LLC. Company insiders that have bought 10x Genomics stock in the last two years include Bryan E Roberts, and Foresite Capital Fund I, LP.
View insider buying and selling activity for 10x Genomics

How do I buy shares of 10x Genomics?

Shares of TXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $99.21.

How big of a company is 10x Genomics?

10x Genomics has a market capitalization of $9.76 billion. 10x Genomics employs 500 workers across the globe.

What is 10x Genomics' official website?

The official website for 10x Genomics is www.10xgenomics.com.

How can I contact 10x Genomics?

The company can be reached via phone at 925-401-7300.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.